PharmaSGP Holding SE

DB:PSG Stock Report

Market Cap: €285.4m

PharmaSGP Holding Past Earnings Performance

Past criteria checks 4/6

PharmaSGP Holding has been growing earnings at an average annual rate of 5.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 14.9% per year. PharmaSGP Holding's return on equity is 50.9%, and it has net margins of 16.5%.

Key information

5.1%

Earnings growth rate

5.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate14.9%
Return on equity50.9%
Net Margin16.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PharmaSGP Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:PSG Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411419580
30 Jun 2411018560
31 Mar 2410718540
31 Dec 2310116510
30 Sep 239815510
30 Jun 239414480
31 Mar 238913460
31 Dec 228612440
30 Sep 228311640
30 Jun 228111420
31 Mar 227411460
31 Dec 216511360
30 Sep 21618360
30 Jun 21568340
31 Mar 21599360
31 Dec 206311350
30 Sep 206516310
30 Jun 206517310
31 Mar 206417220
31 Dec 196317300
31 Dec 186115290
31 Dec 175312280

Quality Earnings: PSG has high quality earnings.

Growing Profit Margin: PSG's current net profit margins (16.5%) are higher than last year (15.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PSG's earnings have grown by 5.1% per year over the past 5 years.

Accelerating Growth: PSG's earnings growth over the past year (25.4%) exceeds its 5-year average (5.1% per year).

Earnings vs Industry: PSG earnings growth over the past year (25.4%) did not outperform the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: Whilst PSG's Return on Equity (50.88%) is outstanding, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:49
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaSGP Holding SE is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard OrgonasBerenberg
Charles WestonRBC Capital Markets
Jack Reynolds-ClarkRBC Capital Markets